AGM PresentationFrançois Martelet, CEO

22 June 2015

NetScientific  today

François Martelet, M.D.

Joined as CEO in June 2015§ Degrees in Medicine, Legal Medicine and Business (France, USA)

Global business experience in big pharma§ Senior level commercial positions at Merck& Co, Inc. and Novartis Pharma, Schering-Plough

and Eli Lilly

Biotech / Biopharma experience§ CEO at Avax Technologies Inc., a US biotech – therapeutic vaccines§ CEO at Topotarget A/S European Biotech - oncology therapeutics§ Senior advisor to CEO Stallergenes SA

3

Pursuing a clear mission

Transatlantic biomedical and healthcare group that funds and develops technologies that offer transformative benefits to people’s lives and society

4

HQ London,  UK

Listing AIM

Symbol NSCI

No.  of  Shares 35,902,020

Shareprice  (19/6/2015) £1.89  

Market Cap  (19/6/2015) £67.9m

5

Well qualified senior management team

Michael Boyce-Jacino, PhDHead of US Investments & Operations

David Gough, MBAHead of EU Investments & Operations

Vijay Barathan, M.D.Investment & Corporate Development

Mark NanovichFinance Director

Peter Thomas FCAChief Financial Officer

Ernest SchneiderGeneral Counsel & Company Secretary

Focused on healthcare

Fund, develop and manage early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe

Primary focus on Digital health, Diagnostics andTherapeutics

Represent highly attractive growth markets where breakthrough technology solutions are in high demand

6

Portfolio

7

Diagnostics

Therapeutics

Delivering actionable information to patients to drive behavioural change Delivering clinical grade data for physicians to drive adoption

Highly specific tests to provide earlier diagnosis, increased monitoring ability and earlier intervention

Next generation therapies

Digital health

Transatlantic Source of opportunities

8

Wallace H. Coulter Foundation has partnered with sixteen university departments of biomedical engineering. Provides non-dilutive funding for selected projects for commercialisation

WH Coulter Foundation Thiel FoundationInstitutions we work with

Peter Thiel’s foundation created Breakout Labs to support companies at the forefront of deep scientific innovation. Provides grant funding to select early-stage companies

Long-standing relationships with leading researchers Strategic partnership

Actions since January 2015

Organisation of senior management team§ Mike Boyce-Jacino heads US operations § David Gough heads EU operations

Portfolio review process completed & rationalisation initiated § Focus on accelerating commercialisation and building value in core assets§ Rationalisation of investments and technology opportunities

Investec appointed as Broker and NOMAD New branding and website Re-launch of NetScientific at the Capital Markets DayCEO appointed

9

2015

9

Looking ahead

Next steps Q3/Q4

Review and strengthen the organization and board

Accelerating top five companies towards commercialisation

Delivering value enhancing news flow across the group

Define clear value inflection points for our major assets

Next update interim results mid September11

2015

11